recent publications

• academic article

  • Lin, K., Gallay, P. Curing a viral infection by targeting the host: The example of cyclophilin inhibitors Antiviral Research  2013 99:68-77  DOI:10.1016/j.antiviral.2013.03.020  PMID:23578729  PMCID:PMC4332838
  • Bobardt, M., Hopkins, S., Baugh, J., Chatterji, U., Hernandez, F., Hiscott, J., Sluder, A., Lin, K., Gallay, P. A. HCV NS5A and IRF9 compete for CypA binding Journal of Hepatology  2013 58:16-23  DOI:10.1016/j.jhep.2012.08.007  PMID:22902549  PMCID:PMC3527675
  • Gallay, P. A., Lin, K. Profile of alisporivir and its potential in the treatment of hepatitis C Drug Design Development and Therapy  2013 7:105-115  DOI:10.2147/dddt.s30946  PMID:23440335  PMCID:PMC3578503
  • Lim, P. J., Chatterji, U., Cordek, D., Sharma, S. D., Garcia-Rivera, J. A., Cameron, C. E., Lin, K., Targett-Adams, P., Gallay, P. A. Correlation between NS5A dimerization and hepatitis C virus replication Journal of Biological Chemistry  2012 287:30861-30873  DOI:10.1074/jbc.M112.376822  PMID:22801423  PMCID:PMC3436329
  • Klionsky, D. J., Abdalla, F. C., Abeliovich, H., Abraham, R. T., Acevedo-Arozena, A., Adeli, K., Agholme, L., Agnello, M., Agostinis, P., Aguirre-Ghiso, J. A., Ahn, H. J., Ait-Mohamed, O., et al. Guidelines for the use and interpretation of assays for monitoring autophagy Autophagy  2012 8:445-544  DOI:10.4161/auto.19496  PMID:22966490  PMCID:PMC3404883
  • Garcia-Rivera, J. A., Bobardt, M., Chatterji, U., Hopkins, S., Gregory, M. A., Wilkinson, B., Lin, K., Gallay, P. A. Multiple mutations in hepatitis C virus NS5A domain II are required to confer a significant level of resistance to alisporivir Antimicrobial Agents and Chemotherapy  2012 56:5113-5121  DOI:10.1128/aac.00919-12  PMID:22802259  PMCID:PMC3457393